Oncology

Back to articles

Axitinib may slightly prolong survival in advanced pancreatic cancer

KEY POINT

 

Research findings recently published in Lancet suggest that gemcitabine (Gemzar—Eli Lilly) plus axitinib (product under development by Pfizer) may slightly but not significantly prolong survival in patients with advanced pan-creatic cancer compared with gemcitabine monotherapy.